A new generation of long-acting injectable (LAI) therapies is reshaping how chronic conditions are treated—shifting the model from daily pills to infrequent injections that offer sustained efficacy. These therapies hold significant promise for improving adherence, clinical outcomes, and the overall patient experience.
At Life Clinical Research, we are actively involved in the evaluation and delivery of these novel treatments through clinical trials across Australia. From psychiatry to cardiovascular disease and infectious disease prevention, long-acting injectables are paving the way for a more patient-centred and streamlined approach to care.
Long-acting injectable therapies are not a new concept. Their roots lie in psychiatry, where monthly and quarterly formulations of antipsychotics have been used for decades to manage conditions such as schizophrenia and bipolar disorder.
Agents like aripiprazole LAI and paliperidone palmitate have demonstrated reduced relapse rates and hospitalisations.
LAIs offer a valuable option for patients who may face challenges with adherence, insight, or complex treatment regimens.
This long-standing success in mental health care has informed the expansion of LAI technologies into other chronic disease areas.
Oral medications remain the cornerstone of chronic disease treatment, but adherence issues driven by forgetfulness, side effects, or pill burden continue to limit effectiveness. LAIs deliver stable drug levels over weeks or months, reducing the frequency of dosing and the risk of missed treatments.
These innovations are designed not just for pharmacological optimisation, but to fit better into the lives of patients.
Inclisiran (siRNA therapy): Twice-yearly dosing, shown to reduce LDL cholesterol significantly.
PCSK9 inhibitors (evolocumab, alirocumab): Monoclonal antibodies dosed every 2–4 weeks with proven cardiovascular benefits.
Factor XIa inhibitors (e.g. abelacimab, milvexian): Novel agents under clinical investigation that may offer long-acting anticoagulation with promising early safety data. These therapies are being studied in orthopaedic surgery, with potential expansion to atrial fibrillation and VTE populations.
GLP-1 receptor agonists (semaglutide, dulaglutide): Weekly formulations improving blood glucose, weight loss, and cardiovascular outcomes.
Tirzepatide & retatrutide: Newer agents in late-stage trials targeting multiple hormone pathways for enhanced effect.
Cabotegravir (HIV PrEP): Administered every two months, showing superior results to daily oral PrEP.
Tuberculosis prophylaxis: Long-acting regimens under development to improve access and adherence in high-risk populations.
CGRP inhibitors (fremanezumab, galcanezumab): Monthly or quarterly injectables that reduce migraine frequency and treatment burden.
Improved adherence: Less frequent dosing leads to better consistency.
- Stable drug levels: Minimise side effects and therapeutic gaps.
- Fewer clinic visits: Especially beneficial for rural or remote populations.
- Reduced stigma and cognitive burden: Discreet treatment and easier routines.
LAI therapies are redefining how clinical trials are conducted:
- Longer endpoints to assess durability.
- Decentralised and digital monitoring.
- Improved recruitment and retention due to patient-friendly regimens.At Life Clinical Research, we are proud to support the development of these therapies and help ensure their successful transition into clinical practice.
Long-acting injectables offer a new paradigm fewer doses, better adherence, and improved outcomes across a wide range of conditions. From psychiatry to cardiometabolic care and infectious disease prevention, these therapies bring innovation directly to the patient.
LCR remains committed to bringing these breakthroughs to life through high-quality, community-based clinical research.
👉 Learn more or participate in a study: https://lcr.health
Disclaimer
This article is for general educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations, and does not create a doctor-patient relationship between the reader and Life Clinical Research or any of its staff. Medical circumstances vary between individuals — always seek advice from a qualified healthcare professional before making decisions about health, treatment, or participation in clinical research. Life Clinical Research accepts no responsibility for actions taken based on this content.